Transgene
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company specializes in viral vector-based technologies, primarily therapeutic vaccines and oncolytic viruses. Transgene's proprietary invir.IO® platform is used to engineer innovative, multifunctional oncolytic viruses designed to modulate the tumor microenvironment and harness the patient's immune system to fight cancer. Its clinical pipeline includes personalized cancer vaccines and armed oncolytic viruses targeting various solid tumors, such as head and neck cancer and colorectal cancer.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Transgene.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-09 17:45 |
Board/Management Information
Transgene nomme une experte de l’industrie pharmaceutique, Emmanuelle Quilès, e…
|
French | 387.4 KB | |
| 2025-07-09 17:45 |
Board/Management Information
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Di…
|
English | 255.1 KB | |
| 2025-06-19 08:00 |
Legal Proceedings Report
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial …
|
English | 310.5 KB | |
| 2025-06-19 08:00 |
Legal Proceedings Report
Transgene finalise la sélection initiale de patients pour la partie Phase II de…
|
French | 304.7 KB | |
| 2025-06-13 08:30 |
Report Publication Announcement
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotec…
|
French | 304.7 KB | |
| 2025-06-13 08:30 |
Report Publication Announcement
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
|
English | 277.0 KB | |
| 2025-06-03 08:00 |
Regulatory News Service
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les c…
|
French | 269.2 KB | |
| 2025-06-03 08:00 |
Report Publication Announcement
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presente…
|
English | 282.5 KB | |
| 2025-06-01 19:15 |
Regulatory News Service
Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une…
|
French | 378.8 KB | |
| 2025-06-01 19:15 |
Earnings Release
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Re…
|
English | 394.4 KB | |
| 2025-05-22 17:45 |
Regulatory News Service
Transgene présente des données de survie sans récidive à 24 mois sur l’ensemble…
|
French | 378.1 KB | |
| 2025-05-22 17:45 |
Regulatory News Service
Transgene to Present 24-month Disease-Free Survival Data from All Patients in P…
|
English | 412.3 KB | |
| 2025-05-15 17:45 |
Post-Annual General Meeting Information
Assemblée Générale Mixte de Transgene du 15 mai 2025
|
French | 315.4 KB | |
| 2025-05-15 17:45 |
Post-Annual General Meeting Information
Transgene's Combined General Meeting of May 15, 2025
|
English | 285.9 KB | |
| 2025-04-24 17:45 |
Business and Financial Review
Transgene Provides Business and Financial Update for Q1 2025
|
English | 310.4 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
